Skip to main content

Data Privacy: More Than Just “The New Black”

Check out Dan Wittenberg’s article on Data Privacy in the Spring 2020 edition of Litigation News – @SWlawnews @abalitigation #cobioscience @cobioscience

| 1 min read

Seven Snell & Wilmer product liability attorneys recognized as leaders in Product Liability Litigation – Defendants by The Best Lawyers in America 2020

Snell & Wilmer recently announced that 143 of the firm’s attorneys were selected by their peers for inclusion in The Best Lawyers in America©. Of those attorneys, seven partners were recognized in the practice area of Product Liability Litigation – Defendants. The 26th edition of The Best Lawyers in America includes attorneys in more than […]

| 1 min read

Snell & Wilmer Attorneys Publish Article on Medical Device Servicing and Remanufacturing

Denver partner Dan Wittenberg and associate Kelly Smith recently published an article, “Clarifying the Difference Between Medical Device Servicing and Remanufacturing,” in DRI’s For the Defense. The article explores the longstanding divide in the medical device industry between device manufacturers and the third-party entities that service the devices. Wittenberg and Smith explain how the FDA […]

| 1 min read

FDA Makes Gene Therapy Available for First Time in USA

Earlier this week, the FDA made gene therapy available for the first time in the United States. This decision, ushers in “a new approach to the treatment of cancer and other serious and life-threatening diseases” said the FDA. The product, Kymriah (tisagenlecleucel), is for certain pediatric and young adult patients with a form of acute […]

| 3 min read

Senate Confirms New FDA Commissioner

Dr. Scott Gottlieb was confirmed today as the new FDA Commissioner.  Dr. Gottlieb has promised to put public health first and not do anything “that shakes the public’s confidence in the agency.” He is a former hospitalist who served in the FDA during the George W. Bush administration, lastly as its deputy commissioner for medical and […]

| 1 min read

One in, Two Out: Potential FDA Uncertainty for Medical Device and Pharmaceutical Companies

By Daniel S. Wittenberg, Co-Chair, Medical Device and Pharmaceutical Industry Group On January 30, 2017, President Trump signed an executive order requiring all governmental agencies to eliminate two regulations for every one issued. The Order, captioned “Reducing Regulation and Controlling Regulatory Costs” specifically states that in an effort to “manage the costs associated with the […]

| 2 min read

Summary of FDA Draft Guidance: Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions

By Daniel S. Wittenberg and Tim Scalo[1] On June 16, 2016, the Food and Drug Administration (FDA) released a draft guidance entitled Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions[2].  The non-binding draft guidance provides clarity to FDA staff and the medical device industry by setting out the benefit […]

| 7 min read

FDA Approves Second Biosimilar – Inflectra™ – The First Monoclonal Antibody Biosimilar

The U.S. Food and Drug Administration announced on April 5 its second ever approval of a biosimilar  –  Inflectra (infliximab-dyyb) – for multiple indications. Inflectra was developed by Celltrion Inc. and licensed to Pfizer Inc., for treatment of rheumatoid arthritis, inflammatory bowel diseases and other conditions.  Inflectra is a biosimilar to Remicade which has been […]

| 3 min read

FDA Issues Final Guidance on Intent to Exempt Certain Medical Devices from Premarket Notification Requirements

On July 1, 2015 the FDA issued its final guidance regarding the intent to exempt certain unclassified medical devices, certain Class II medical devices, and certain Class I medical devices that are subject to the reserved criteria of section 510(l) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 360(l), from premarket […]

| 5 min read

Adopting a Safety Policy and Assembling a Safety Team

Large or small, every life science or medical technology company will eventually have to deal with a products liability claim or event. A lack of adequate planning for such an occurrence can result in damage to the brand, loss of consumer confidence, harm to the business and trigger potential regulatory consequences as well as result in […]

| 6 min read